Nicox SA Share from reverse split NICXF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.64
- Day Range
- $0.44–0.44
- 52-Week Range
- $0.44–0.89
- Bid/Ask
- $0.44 / $0.52
- Market Cap
- $22.07 Mil
- Volume/Avg
- 100 / 100
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.50
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 28
- Website
- https://www.nicox.com
Valuation
|
Metric
|
NICXF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.45 |
Price/Sales | 3.50 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NICXF
|
|---|---|
Quick Ratio | 2.34 |
Current Ratio | 2.57 |
Interest Coverage | −9.59 |
Quick Ratio
NICXF
Profitability
|
Metric
|
NICXF
|
|---|---|
Return on Assets (Normalized) | −20.52% |
Return on Equity (Normalized) | −35.53% |
Return on Invested Capital (Normalized) | −23.44% |
Return on Assets
NICXF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zwkcrfzlv | Rssf | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Yktzmfhs | Jjfffq | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nhpkbvpg | Bzdql | $99.5 Bil | |
MRNA
| Moderna Inc | Ckgtslry | Btxf | $38.8 Bil | |
ARGX
| argenx SE ADR | Zkzhxcdv | Llrb | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Xrszmyx | Kbkp | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bzgvtqlf | Shgkgt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yfqlnvbqh | Prkty | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Ctqbprwrqb | Vpzsxq | $12.5 Bil | |
INCY
| Incyte Corp | Zwmdjcq | Xbgyz | $11.6 Bil |